Pharmaceutical

AriBio licenses Alzheimer’s pill in China for up to $770m

An unnamed Chinese partner takes on AR1001 in an APAC Alzheimer’s market predicted to be worth $2.6bn by 2030

Mar 26, 2024 - 00:00
AriBio licenses Alzheimer’s pill in China for up to $770m
An unnamed Chinese partner takes on AR1001 in an APAC Alzheimer’s market predicted to be worth $2.6bn by 2030
Read the original article

Tags:

Previous Article

Esperion snags US label expansion for cardiovascular disease drugs

Next Article

Birmingham University to develop lollipop for mouth cancer detection

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

test

Apr 16, 2023

Pyxis cuts staff by 40% and pours resources into two cancer therapies

Pyxis cuts staff by 40% and pours resources into two ca...

Nov 8, 2023

STAT+: PhRMA execs paint grim picture of industry under Medicare drug price negotiation

STAT+: PhRMA execs paint grim picture of industry under...

Apr 19, 2023